mRNA-1469A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants

Sponsor:

Moderna

Code:

NCT07737717

Conditions

Ebola-Bundibugyo Virus Disease (Ebola-BDBV)

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

mRNA-1469

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by ModernaTX, Inc. on 2026-08-11.